timothy sykes logo

Stock News

RNAZ’s Bold Move: What’s Next?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 3/21/2025, 9:18 am ET 5 min read
RNAZ’s Bold Move: What’s Next? Thumbnail

TransCode Therapeutics Inc.’s stock price saw a significant boost Friday thanks to news that could include positive developments in clinical trials or strategic company announcements, trading up by 34.42 percent.

Key Developments at TransCode Therapeutics

  • The favorable safety review for TransCode Therapeutics’ cancer trial paved the way for their Phase 1/2 trial to open its fourth cohort. The therapy, known as TTX-MC138, targets multiple metastatic cancers using antisense technology and will have an increased dosage for this phase.

Candlestick Chart

Live Update At 09:18:06 EST: On Friday, March 21, 2025 TransCode Therapeutics Inc. stock [NASDAQ: RNAZ] is trending up by 34.42%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • TransCode Therapeutics received a nod to proceed with the next patient group in its Phase 1 trial, buoyed by promising safety outcomes from earlier evaluations.

  • Approval from the Safety Review Committee has been granted to start the fourth cohort in the ongoing cancer trial, reinforcing the growing focus on antisense technology in tackling metastatic cancers.

  • Shareholder confidence surged following critical proposal endorsements, shining light on TransCode’s direction toward strategic growth.

Quick Overview of Recent Financials

As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This philosophy is essential for traders as they navigate the volatile world of trading. Learning from mistakes is crucial, as it enables traders to refine their methods and strategies over time. Embracing the process and understanding that both successes and failures contribute to one’s overall experience can lead to better decision-making and improved outcomes in the future.

TransCode Therapeutics Inc. recently reported its financial metrics, unveiling some intriguing aspects despite the market turbulence. Having a current ratio of 1.6 hints at a reasonable liquidity position. However, with a return on assets standing at -108.87%, it’s evident there are struggles defensively from previous periods. The leverage ratio and working capital show strength in control and operational efficiency. Their quick ratio, indicating short-term financial stability, sits at 0.8 – albeit a tad concerning but manageable with existing assets. The firm’s valuation metrics, shedding light on enterprise worth, showcase an intriguing space with negative enterprise value yet steady pricing metrics.

More Breaking News

From the financial reports, changes in cash were prominently due to continued investments and strategic asset allocations, aligning with future growth aspirations. Trading at relatively low levels, with recent dips and swings as seen in the recent price chart data, presents the firm as a volatile yet appealing option for keen market observers.

Strategic Implications of the Trial Expansion

TransCode Therapeutics’ bold move to escalate its TTX-MC138 therapy trial brings about broader market attention. This technology derived from antisense methodology could be a game-changer if it successfully demonstrates its efficacy in treating challenging metastatic cancers. Investors keep a close eye on these developments, hoping the therapeutic advancements herald promising returns and foster long-term company stability.

Prevailing financial reports, alongside ongoing strategic moves, present a mixed sentiment canvas. Though there are signs of promising research progress, the road remains thorny with financial metrics showing areas needing reinforcement.

Concluding Thoughts

In sum, TransCode Therapeutics not only harnesses the potential of advanced cancer therapies but also navigates through a complex financial landscape. Current stock movements display volatility, with fresh trial advancements potentially swaying future valuation and trader sentiment. Whether it is the swelling anticipation from trial outcomes or the jitteriness of stock volatility, what’s unequivocal is that RNAZ remains on the market radar for its bold and audacious strategies amidst a fiercely competitive field.

As the company continues on its path, the calculated steps forward must balance research vision with fiscal prudence to truly resonate in both the market and healthcare arenas. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” This philosophy is particularly pertinent for traders navigating this volatile environment, emphasizing the importance of strategic trading decisions to secure lasting success.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.